Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

Marilyn Weiler treated the Monday Senior Lunch Bunch to an hour of curious and humorous bird sayings and expressions on Feb.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Opinion: Margaret Atwood's premise seemed outrageous to me in 1984, but Iowa overreach makes it more believable, writes ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

A fun evening of wine and self-defense training will also support a good cause next week as Cote Winery hosts its second annual self-defense class benefiting Safe Harbor Peer Support Services.

We provide more details on some of the top companies in the Nasdaq 100 index that are dragging the QQQ ETF this year.

Renaissance Technologies' 13F reveals shifts in a $67.6B portfolio with notable changes in Palantir, Novo Nordisk, and NVIDIA ...

I was in high school when I first read "The Handmaid's Tale" by Margaret Atwood. Having been coddled by the strong feminist ...